Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $208.1K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RNAZ, Q2 2026
No superinvestor reported holding RNAZ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Transcode Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Fitzgerald Thomas AChief Financial Officer | PPurchase | +49.4K | $0.51 | +$25.2K | +708.2%56.3K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +98.0K | $0.51 | +$50.0K | +119.1%180.3K after | |
| Jun 22, 2023 (view filing) | Jun 20-21 | 2 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +18.6K | $2.61 | +$48.6K | +29.2%82.3K after | 2 lots |
| Jun 14, 2023 (view filing) | Jun 9 | 5 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +19.0K | $2.76 | +$52.4K | +45.1%61.2K after | Amended |
| Sep 16, 2022 (view filing) | Sep 14 | 2 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +20.0K | $1.15 | +$23.0K | +2.3%893.1K after | |
| Jun 17, 2022 (view filing) | Jun 16 | 1 day | Fitzgerald Thomas AChief Financial Officer | PPurchase | +12.0K | $1.27 | +$15.2K | +9.4%139.4K after | |
| Jun 1, 2022 (view filing) | May 27-31 | 5 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +30.0K | $1.84 | +$55.3K | +3.6%873.1K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Transcode Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | $122.0K | 0.14% | +19,639 | New |
| Vanguard Capital Management LLC | 6,545 | $40.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 2,982 | $18.5K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,888 | $17.9K | 0.00% | −5,407−65.2% | Reduced |
| FMR LLC | 706 | $4.38K | 0.00% | +706 | New |
| Tower Research Capital LLC (TRC) | 677 | $4.20K | 0.00% | +449+196.9% | Added |
| Wells Fargo & Company | 55 | $342 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 12 | $75 | 0.00% | 00.0% | Unchanged |